AEON Biopharma, Inc. granted 392,158 restricted stock units (RSUs) to new non-executive employees in December 2025. The RSUs vest over four years, with 25% vesting annually starting December 2025. This grant was made under the 2025 Inducement Incentive Plan, approved by the Company’s Board of Directors.

The U.S. FDA regulates biosimilars like ABP-450 under the 351(k) pathway, requiring developers to show high similarity to an approved reference biologic. Analytical similarity is key, followed by limited clinical evaluation. AEON Biopharma is pursuing full-label entry into the U.S. therapeutic neurotoxin market with ABP-450, a BOTOX biosimilar.

AEON Biopharma holds exclusive rights for ABP-450 in the U.S., Canada, EU, UK, and other territories. The product is manufactured by Daewoong Pharmaceutical and approved as a biosimilar in India, Mexico, and the Philippines. For more information, visit www.aeonbiopharma.com.

Read more at GlobeNewswire: AEON Biopharma Reports Inducement Grants Under NYSE